. RATIONALE: Nei-like 2 (NEIL2) is a DNA glycosylase enzyme that can excise oxidized damaged DNA bases like 5-hydroxyuracil. Neil2-null mice show more innate inflammatory response in the lungs stimulated by oxidative stress-inducing challenges. Here we hypothesized that NEIL2 regulates cat dander extract (CDE)-induced allergic airway inflammation and sensitization. METHODS: Wild-type (WT) and Neil2 KO mice were sensitized with 5 intranasal doses of CDE and challenged with CDE to elucidate allergic airway inflammation. Allergic airway inflammation and the lung mRNA expression of 84 genes known to be associated with allergic-inflammation were quantified. RESULTS: Multiple challenge with CDE in WT mice induced allergic inflammation characterized by an increase in eosinophilic airway inflammation, stimulation of mucin in airway epithelial cells, and levels of cat dander specific IgE in serum at 72-hours post challenge. Multiple CDE challenges in Neil2 KO mice enhanced these increases observed in WT mice. PCR array and qPCR identified Ccl11 and Il5ra as two eosinophilia-associated genes that were higher 4 h-post challenge in Neil2 KO mice. CONCLUSIONS: These observations indicates that NEIL2 suppress CDE-induced eosinophilic airway inflammation. NEIL2 may be a novel target for attenuating eosinophilic airway inflammation and antigenspecific IgE. Children's Hospital of Philadelphia, Philadelphia, PA. RATIONALE: Eosinophilic esophagitis (EoE) is a multifactorial, chronic esophageal disorder characterized by epithelial barrier dysfunction and eosinophil-predominant allergic inflammation. The precise mechanisms that sustain epithelial barrier dysfunction and inflammation in EoE are poorly understood. The esophageal epithelium expresses functional Tolllike receptors (TLR), which are a family of Pattern recognition receptors (PRR). The objective of these studies was to investigate the effect of TLR2 agonist treatment on esophageal epithelial barrier function. METHODS: Immortalized human esophageal epithelial cells were stimulated with TLR2 agonists in an in vitro air-liquid interface (ALI) epithelial model system. We then used transepithelial electrical resistance (TEER) and permeability to FITC-labeled dextran were used to assess membrane barrier function following TLR2 stimulation. RESULTS: Primary and EPC2-hTERT esophageal epithelial cells express high levels of TLR2 and TLR3. TLR2 stimulation led to increased transepithelial electrical resistance (1.4-fold) and decreased paracellular permeability to FITC-Dextran. ALI cultures treated with zymosan have altered epithelial architecture. TJ-proteins are specifically induced after treatment with TLR2 agonist zymosan, with induction of claudin-1 (3.9-fold) and zonula occludens 1 (2.7-fold) gene expression. Chromatin immunoprecipitation analysis demonstrated significant increase in H4ac at the CLDN1 enhancer and promoter following stimulation of EPC2-hTERT with zymosan, indicating that durable chromatin changes occur following TLR2 stimulation in esophageal epithelium. CONCLUSIONS: In these studies, we demonstrate a unique role for esophageal TLR2 stimulation in upregulating cell-cell adhesion proteins, thereby improving the epithelial barrier function.
Children's Hospital of Philadelphia, Philadelphia, PA. RATIONALE: Eosinophilic esophagitis (EoE) is a multifactorial, chronic esophageal disorder characterized by epithelial barrier dysfunction and eosinophil-predominant allergic inflammation. The precise mechanisms that sustain epithelial barrier dysfunction and inflammation in EoE are poorly understood. The esophageal epithelium expresses functional Tolllike receptors (TLR), which are a family of Pattern recognition receptors (PRR). The objective of these studies was to investigate the effect of TLR2 agonist treatment on esophageal epithelial barrier function. METHODS: Immortalized human esophageal epithelial cells were stimulated with TLR2 agonists in an in vitro air-liquid interface (ALI) epithelial model system. We then used transepithelial electrical resistance (TEER) and permeability to FITC-labeled dextran were used to assess membrane barrier function following TLR2 stimulation. RESULTS: Primary and EPC2-hTERT esophageal epithelial cells express high levels of TLR2 and TLR3. TLR2 stimulation led to increased transepithelial electrical resistance (1.4-fold) and decreased paracellular permeability to FITC-Dextran. ALI cultures treated with zymosan have altered epithelial architecture. TJ-proteins are specifically induced after treatment with TLR2 agonist zymosan, with induction of claudin-1 (3.9-fold) and zonula occludens 1 (2.7-fold) gene expression. Chromatin immunoprecipitation analysis demonstrated significant increase in H4ac at the CLDN1 enhancer and promoter following stimulation of EPC2-hTERT with zymosan, indicating that durable chromatin changes occur following TLR2 stimulation in esophageal epithelium. CONCLUSIONS: In these studies, we demonstrate a unique role for esophageal TLR2 stimulation in upregulating cell-cell adhesion proteins, thereby improving the epithelial barrier function.
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Steroid-Dependent Episodic Angioedema with Eosinophilia (Gleich Syndrome) in a Patient with Rheumatoid Arthritis Sheeba K. Cherian, MD, Jason Springer, MD, and Sadia Hayat, MD; University of Kansas Medical Center, Kansas City, KS. RATIONALE: Episodic angioedema with eosinophilia, or Gleich syndrome, is a rare disorder characterized by periodic episodes of angioedema and leukocytosis with marked eosinophilia. Symptoms resolve spontaneously or are treated with corticosteroids as first-line therapy. Treatment of patients unresponsive to or dependent on corticosteroids is poorly defined. Several rheumatologic diseases, including rheumatoid arthritis (RA), can also present with elevated eosinophilia in blood or tissue. Here we present a case of steroid-dependent Gleich syndrome complicated by concurrent rheumatoid arthritis. METHODS: A retrospective chart review of a patient with Gleich syndrome at a university hospital-based Allergy/Immunology outpatient clinic in Kansas City, KS. RESULTS: This patient with seropositive RA had multiple episodes of angioedema with eosinophilia and associated dyspnea. Labs showed absolute eosinophil count of 12.9 K/UL and WBC 25.51 K/UL. Tryptase was elevated at 26.1 ug/L. CT neck showed subglottic swelling. Further workup included normal ACE and C1 esterase inhibitor levels and negative ANCA serologies. Bone marrow biopsy showed hypercellular marrow and normal cytogenetics. A diagnosis of Gleich syndrome was suspected. She was initially treated with glucocorticoids but with attempts at weaning experienced recurrent pharyngeal swelling and increase in serum eosinophilia. She was then started on rituximab for RA and hypereosinophilia with decrease in eosinophil count and ability to tolerate further steroid tapers. CONCLUSIONS: To our knowledge, this is the first reported case of Gleich syndrome in a patient with RA. Rituximab therapy has been described in hypereosinophilic syndromes but not reported specifically for Gleich syndrome, demonstrating the importance of recognizing alternative therapies for complex, steroid-dependent disease.
